Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:1071-1076, 2006
DOI: 10.2337/dc05-2174
© 2006 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Esposito, K.
Right arrow Articles by Giugliano, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esposito, K.
Right arrow Articles by Giugliano, D.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cardiovascular and Metabolic Risk
Original Article

Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome

Katherine Esposito, MD, PHD1,2, Miryam Ciotola, MD1, Diego Carleo, MD1, Bruno Schisano, BT1, Franco Saccomanno, MD1, Ferdinando Carlo Sasso, MD3, Domenico Cozzolino, MD3, Roberta Assaloni, MD4, Domenico Merante, MD5, Antonio Ceriello, MD4 and Dario Giugliano, MD, PHD1,2

1 Division of Metabolic Diseases, University of Naples SUN, Naples, Italy
2 Centro di Eccellenza Cardiovascolare, University of Naples SUN, Naples, Italy
3 Department of Geriatrics and Metabolic Diseases, University of Naples SUN, Naples, Italy
4 Department of Internal Medicine, University of Udine, Udine, Italy
5 Medical Department, GlaxoSmithKline, Verona, Italy

Address correspondence and reprint requests to Dario Giugliano, MD, PhD, Chair and Division of Metabolic Diseases, Policlinico Seconda Università di Napoli, Piazza L. Miraglia, 80031 Naples, Italy. E-mail: dario.giugliano{at}unina2.it

OBJECTIVE—The aim of this study was to assess the effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.

RESEARCH DESIGN AND METHODS—This was a randomized, double-blind, controlled clinical trial. One hundred subjects (54 men and 46 women) with the metabolic syndrome, as defined by the Adult Treatment Panel III, were followed for 12 months after random assignment to rosiglitazone (4 mg/day) or placebo. Primary end points were flow-mediated dilation and high-sensitivity C-reactive protein (hs-CRP) levels; secondary end points were lipid and glucose parameters, homeostasis model assessment (HOMA) of insulin sensitivity, endothelial function score, and circulating levels of interleukin (IL)-6, IL-18, and adiponectin.

RESULTS—Compared with 60 control subjects matched for age and sex, patients with the metabolic syndrome had decreased endothelial function, raised concentrations of inflammatory markers, and reduced insulin sensitivity. After 12 months, subjects with the metabolic syndrome receiving rosiglitazone showed improved flow-mediated vasodilation (4.2%, P < 0.001) and reduced hs-CRP levels (–0.7 mg/dl, P = 0.04), compared with the placebo group. Moreover, HOMA (–0.8, P = 0.01) and serum concentrations of IL-6 (–0.5 pg/ml, P = 0.045) and IL-18 (–31 pg/ml, P = 0.036) were significantly reduced in subjects receiving rosiglitazone, whereas adiponectin levels showed a significant increment (2.3 µg/ml, P = 0.02). High-density lipoprotein-cholesterol levels increased more and triglyceride levels decreased more in the rosiglitazone group compared with the placebo group. At 1 year of follow-up, 30 subjects receiving rosiglitazone still had features of the metabolic syndrome, compared with 45 subjects receiving placebo (P < 0.001).

CONCLUSIONS—Rosiglitazone might be effective in reducing the prevalence of the metabolic syndrome.

Abbreviations: CRP, C-reactive protein • FMD, flow-mediated vasodilation • HOMA, homeostasis model assessment • hs-CRP, high-sensitivity CRP • IL, interleukin


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
D. Giugliano, A. Ceriello, and K. Esposito
Are there specific treatments for the metabolic syndrome?
Am. J. Clinical Nutrition, January 1, 2008; 87(1): 8 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
A. S. Kelly, A. M. Thelen, D. R. Kaiser, J. M. Gonzalez-Campoy, and A. J. Bank
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
Vascular Medicine, November 1, 2007; 12(4): 311 - 318.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
N. P.E. Kadoglou, F. Iliadis, C. D. Liapis, D. Perrea, N. Angelopoulou, and M. Alevizos
Beneficial Effects of Combined Treatment With Rosiglitazone and Exercise on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Diabetes Care, September 1, 2007; 30(9): 2242 - 2244.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon
Cardiovascular Actions of Insulin
Endocr. Rev., August 1, 2007; 28(5): 463 - 491.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
S. Gharibzadeh and S. S. Hoseini
A Novel View on the Pharmacodynamics of Rosiglitazone and Introducing Some Potential Drugs in Ameliorating Alzheimer's Disease
J Neuropsychiatry Clin Neurosci, August 1, 2007; 19(3): 349 - 349.
[Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. D. Knudson, G. M. Dick, and J. D. Tune
Adipokines and Coronary Vasomotor Dysfunction
Experimental Biology and Medicine, June 1, 2007; 232(6): 727 - 736.
[Abstract] [Full Text] [PDF]

Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
M. G. Flynn, B. K. McFarlin, and M. M. Markofski
State of the Art Reviews: The Anti-Inflammatory Actions of Exercise Training
American Journal of Lifestyle Medicine, May 1, 2007; 1(3): 220 - 235.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
S. G. Wannamethee, G. D.O. Lowe, A. Rumley, L. Cherry, P. H. Whincup, and N. Sattar
Adipokines and Risk of Type 2 Diabetes in Older Men
Diabetes Care, May 1, 2007; 30(5): 1200 - 1205.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. Esteve, A. Castro, A. Lopez-Bermejo, J. Vendrell, W. Ricart, and J.-M. Fernandez-Real
Serum Interleukin-6 Correlates With Endothelial Dysfunction in Healthy Men Independently of Insulin Sensitivity
Diabetes Care, April 1, 2007; 30(4): 939 - 945.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Esposito, M. Ciotola, B. Schisano, R. Gualdiero, L. Sardelli, L. Misso, G. Giannetti, and D. Giugliano
Endothelial Microparticles Correlate with Endothelial Dysfunction in Obese Women
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3676 - 3679.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
K. Esposito, M. Ciotola, and D. Giugliano
Pioglitazone reduces endothelial microparticles in the metabolic syndrome.
Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1926 - 1926.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2006 by the American Diabetes Association.